Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial

H. Navabi, D. Croston, J. Hobot, A. Clayton, L. Zitvogel, B. Jasani, R. Bailey-Wood, K. Wilson, Z. Tabi, M. D. Mason, M. Adams

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Despite initial response to chemotherapy, at least 50% of ovarian cancer patients will relapse within 18 months. Progression-free survival is related to tumour infiltration with cytotoxic T lymphocytes (CTL). We recently demonstrated that CD8+ T cell responses to recall antigens improve following tumour response to chemotherapy. Vaccination designed to expand CTL, specific for tumour-associated antigens, may be a means of improving outcome. We are planning a clinical trial in advanced ovarian cancer patients undergoing chemotherapy using a combination of a Toll-like receptor 3 (TLR3) agonist and tumour-associated ascites-derived exosomes. Tumour-derived exosomes are a potential source of tumour antigens able to induce CD8+ T cell responses when loaded on mature dendritic cells (DC). DC maturation can be achieved with Toll-like receptor (TLR) agonists, such as the GMP-grade synthetic double stranded RNA, poly[I]:poly[C12U] (Ampligen®) which is a TLR-3 agonist. Here, we describe the development of a method suitable for the preparation of GMP-grade exosomes from the ascites fluid of ovarian cancer patients, and the methods used for the molecular and immunological characterisation of these exosomes preceding their use in a clinical trial.

Original languageEnglish
Pages (from-to)149-152
Number of pages4
JournalBlood Cells, Molecules, and Diseases
Volume35
Issue number2
DOIs
Publication statusPublished - Sep 2005
Externally publishedYes

Fingerprint

Exosomes
Ascites
Ovarian Neoplasms
Toll-Like Receptor 3
Clinical Trials
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Drug Therapy
Dendritic Cells
Neoplasms
T-Lymphocytes
Double-Stranded RNA
Toll-Like Receptors
Disease-Free Survival
Vaccination
Antigens
Recurrence
poly(I).poly(c12,U)

Keywords

  • Ascites-derived exosomes
  • Clinical trial
  • Ovarian cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Cite this

Navabi, H., Croston, D., Hobot, J., Clayton, A., Zitvogel, L., Jasani, B., ... Adams, M. (2005). Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases, 35(2), 149-152. https://doi.org/10.1016/j.bcmd.2005.06.008

Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. / Navabi, H.; Croston, D.; Hobot, J.; Clayton, A.; Zitvogel, L.; Jasani, B.; Bailey-Wood, R.; Wilson, K.; Tabi, Z.; Mason, M. D.; Adams, M.

In: Blood Cells, Molecules, and Diseases, Vol. 35, No. 2, 09.2005, p. 149-152.

Research output: Contribution to journalArticle

Navabi, H, Croston, D, Hobot, J, Clayton, A, Zitvogel, L, Jasani, B, Bailey-Wood, R, Wilson, K, Tabi, Z, Mason, MD & Adams, M 2005, 'Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial', Blood Cells, Molecules, and Diseases, vol. 35, no. 2, pp. 149-152. https://doi.org/10.1016/j.bcmd.2005.06.008
Navabi, H. ; Croston, D. ; Hobot, J. ; Clayton, A. ; Zitvogel, L. ; Jasani, B. ; Bailey-Wood, R. ; Wilson, K. ; Tabi, Z. ; Mason, M. D. ; Adams, M. / Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. In: Blood Cells, Molecules, and Diseases. 2005 ; Vol. 35, No. 2. pp. 149-152.
@article{0e0f7a4192c845b5943bff3a5512ea61,
title = "Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial",
abstract = "Despite initial response to chemotherapy, at least 50{\%} of ovarian cancer patients will relapse within 18 months. Progression-free survival is related to tumour infiltration with cytotoxic T lymphocytes (CTL). We recently demonstrated that CD8+ T cell responses to recall antigens improve following tumour response to chemotherapy. Vaccination designed to expand CTL, specific for tumour-associated antigens, may be a means of improving outcome. We are planning a clinical trial in advanced ovarian cancer patients undergoing chemotherapy using a combination of a Toll-like receptor 3 (TLR3) agonist and tumour-associated ascites-derived exosomes. Tumour-derived exosomes are a potential source of tumour antigens able to induce CD8+ T cell responses when loaded on mature dendritic cells (DC). DC maturation can be achieved with Toll-like receptor (TLR) agonists, such as the GMP-grade synthetic double stranded RNA, poly[I]:poly[C12U] (Ampligen{\circledR}) which is a TLR-3 agonist. Here, we describe the development of a method suitable for the preparation of GMP-grade exosomes from the ascites fluid of ovarian cancer patients, and the methods used for the molecular and immunological characterisation of these exosomes preceding their use in a clinical trial.",
keywords = "Ascites-derived exosomes, Clinical trial, Ovarian cancer",
author = "H. Navabi and D. Croston and J. Hobot and A. Clayton and L. Zitvogel and B. Jasani and R. Bailey-Wood and K. Wilson and Z. Tabi and Mason, {M. D.} and M. Adams",
year = "2005",
month = "9",
doi = "10.1016/j.bcmd.2005.06.008",
language = "English",
volume = "35",
pages = "149--152",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial

AU - Navabi, H.

AU - Croston, D.

AU - Hobot, J.

AU - Clayton, A.

AU - Zitvogel, L.

AU - Jasani, B.

AU - Bailey-Wood, R.

AU - Wilson, K.

AU - Tabi, Z.

AU - Mason, M. D.

AU - Adams, M.

PY - 2005/9

Y1 - 2005/9

N2 - Despite initial response to chemotherapy, at least 50% of ovarian cancer patients will relapse within 18 months. Progression-free survival is related to tumour infiltration with cytotoxic T lymphocytes (CTL). We recently demonstrated that CD8+ T cell responses to recall antigens improve following tumour response to chemotherapy. Vaccination designed to expand CTL, specific for tumour-associated antigens, may be a means of improving outcome. We are planning a clinical trial in advanced ovarian cancer patients undergoing chemotherapy using a combination of a Toll-like receptor 3 (TLR3) agonist and tumour-associated ascites-derived exosomes. Tumour-derived exosomes are a potential source of tumour antigens able to induce CD8+ T cell responses when loaded on mature dendritic cells (DC). DC maturation can be achieved with Toll-like receptor (TLR) agonists, such as the GMP-grade synthetic double stranded RNA, poly[I]:poly[C12U] (Ampligen®) which is a TLR-3 agonist. Here, we describe the development of a method suitable for the preparation of GMP-grade exosomes from the ascites fluid of ovarian cancer patients, and the methods used for the molecular and immunological characterisation of these exosomes preceding their use in a clinical trial.

AB - Despite initial response to chemotherapy, at least 50% of ovarian cancer patients will relapse within 18 months. Progression-free survival is related to tumour infiltration with cytotoxic T lymphocytes (CTL). We recently demonstrated that CD8+ T cell responses to recall antigens improve following tumour response to chemotherapy. Vaccination designed to expand CTL, specific for tumour-associated antigens, may be a means of improving outcome. We are planning a clinical trial in advanced ovarian cancer patients undergoing chemotherapy using a combination of a Toll-like receptor 3 (TLR3) agonist and tumour-associated ascites-derived exosomes. Tumour-derived exosomes are a potential source of tumour antigens able to induce CD8+ T cell responses when loaded on mature dendritic cells (DC). DC maturation can be achieved with Toll-like receptor (TLR) agonists, such as the GMP-grade synthetic double stranded RNA, poly[I]:poly[C12U] (Ampligen®) which is a TLR-3 agonist. Here, we describe the development of a method suitable for the preparation of GMP-grade exosomes from the ascites fluid of ovarian cancer patients, and the methods used for the molecular and immunological characterisation of these exosomes preceding their use in a clinical trial.

KW - Ascites-derived exosomes

KW - Clinical trial

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=24644445037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644445037&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2005.06.008

DO - 10.1016/j.bcmd.2005.06.008

M3 - Article

C2 - 16061407

AN - SCOPUS:24644445037

VL - 35

SP - 149

EP - 152

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 2

ER -